Takeda Oncology
Pablo Povea Molinero has extensive experience in the pharmaceutical industry, specializing in oncology and hospital pharmacy. Currently serving as KAM ONCOLOGIA at Takeda Oncology since September 2015, Pablo previously held various key positions at GlaxoSmithKline from January 2001 to March 2015, including KAM GSK ONCOLOGIA and DELEGADO ONCO-HEMATOLOGIA. Throughout this tenure, Pablo demonstrated expertise in launching oncology products such as Votrient and Revolade, achieving high performance ratings, including "Excelente" in 2013. Previous roles also encompass significant responsibilities in introducing new medications across diverse specialties, particularly in hospital environments. Pablo began a career in pharma at Glaxo Wellcome from 1995 to 2001, working as a DELEGADO ATENCION PRIMARIA Y RESPIRATORIO, earning recognition through multiple awards.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.